Calendar Year (CY) 2019 Annual Update for Clinical Laboratory Fee Schedule and Laboratory Services Subject to Reasonable Charge Payment

MLN Matters Number: MM11076  Related Change Request (CR) Number: 11076
Related CR Release Date: January 17, 2019  Effective Date: January 1, 2019
Related CR Transmittal Number: R4208CP  Implementation Date: January 7, 2019

Note: We revised this article on January 14, 2020, to add a link to a related article SE19006. SE19006 states that for CDLTs that are not ADLTs, the data reporting is delayed by one year and must now be reported between January 1, 2021, and March 31, 2021 (previously January 1, 2020, through March 31, 2020). The article also added the “CLFS Data Reporting Delayed” Section on page 24 to summarize the changes. All other information remains the same.

PROVIDER TYPES AFFECTED

This MLN Matters Article is intended for clinical diagnostic laboratories that submit claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

PROVIDER ACTION NEEDED

CR 11076 provides instructions for the Calendar Year (CY) 2019 Clinical Laboratory Fee Schedule (CLFS), mapping for new codes for clinical laboratory tests, and updates for laboratory costs subject to the reasonable charge payment. Make sure your billing staffs are aware of these updates.

BACKGROUND

The CY 2019 updates are as follows:

Next CLFS Data Collection Period

Section 1834A of the Social Security Act ("the Act"), as established by Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA), required significant changes to how Medicare pays for Clinical Diagnostic Laboratory Tests (CDLTs) under the CLFS. The CLFS final rule, “Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule," (CMS-162-F) was published in the Federal Register on June 23, 2016. The CLFS final rule implemented Section 1834A of the Act.

Under the CLFS final rule, reporting entities must report to the Centers for Medicare & Medicaid Services (CMS) certain private payer rate information (applicable information) for their component applicable laboratories. The next data collection period (the period where applicable information for an applicable laboratory is obtained from claims for which the laboratory received final payment during the period) is from January 1, 2019, through June 30, 2019, and the next 6-month window is July 1, 2019, through December 31, 2019 (the period where laboratories and
reporting entities assess whether the applicable laboratory thresholds are met and review and validate applicable information before it is reported to CMS).

The next data-reporting period is January 1, 2020, through March 31, 2020, where applicable information is reported to CMS. This data will be used to calculate revised private payer rate-based CLFS rates, effective January 1, 2021. Specific directions on data collection and data reporting are available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/PAMA-regulations.html.

**Revisions to the Definition of Applicable Laboratory**

The Physician Fee Schedule (PFS) final rule entitled, “Revisions to Payment Policies under the Medicare Physician Fee Schedule, Quality Payment Program and Other Revisions to Part B for CY 2019,” (CMS-1693-F) was displayed in the Federal Register on November 1, 2018, and was published on November 23, 2018. In the CY 2019 PFS final rule, CMS made two revisions to the regulatory definition of Applicable Laboratory:

1. Effective January 1, 2019, Medicare Advantage plan revenues are excluded from total Medicare revenues (the denominator of the majority of Medicare revenues threshold); and
2. Effective January 1, 2019, hospitals that bill for their non-patient laboratory services may use Medicare revenues from the Form CMS-1450 14x Type of Bill (TOB) to determine whether its hospital outreach laboratories meet the majority of Medicare revenues threshold and low-expenditure threshold.

Effective January 1, 2019, the regulatory definition of an applicable laboratory is summarized below. An applicable laboratory means an entity that:

1. Is a laboratory as defined under the Clinical Laboratory Improvement Amendments (CLIA) regulatory definition of a laboratory (42 CFR Section 493.2);

2. The laboratory bills Medicare under its own National Provider Identifier (NPI) or
   a. For hospital outreach laboratories: Bills Medicare Part B on the Form CMS-1450 under TOB 14x

3. The laboratory must meet a “majority of Medicare revenues,” threshold, where it receives more than 50 percent of its total Medicare revenues from one or a combination of the CLFS or the PFS in a data collection period. For purposes of determining whether a laboratory meets the “majority of Medicare revenues” threshold, total Medicare revenues includes: fee-for-service payments under Medicare Parts A and B, prescription drug payments under Medicare Part D, and any associated Medicare beneficiary deductible or coinsurance. **Effective January 1, 2019, total Medicare revenues no longer includes Medicare Advantage payments under Medicare Part C.**

4. The laboratory must meet a “low expenditure” threshold, where it receives at least $12,500 of its Medicare revenues from the CLFS in a data collection period.
Coding for Health Common Procedure Coding System (HCPCS)
Panel Codes

As laboratories are aware, the implementation of PAMA required Medicare to pay the weighted median of private payer rates for each separate HCPCS code. Prior to PAMA implementation, CMS paid for certain chemistry tests using Automated Test Panels (ATPs), which used claims processing logic to apply a bundled rate to sets of these codes, depending on how many of these chemistry tests were ordered. This logic no longer exists under PAMA guidelines. HCPCS codes include those from the AMA Current Procedural Technology (CPT) Manual, that are in the category of Organ or Disease Oriented panels, which are panels that consist of groups of specified tests. Because CMS no longer has payment logic to roll up panel pricing, laboratories shall report the panel test where appropriate and not report separately the tests that make up that panel. This is also consistent with recent changes in CMS’s National Correct Coding Initiative (NCCI) manual. For example, if the individually ordered tests are cholesterol (CPT code 82465), triglycerides (CPT code 84478), and HDL cholesterol (CPT code 83718), the service shall be reported as a lipid panel (CPT code 80061). If the laboratory repeats one of these component tests as a medically reasonable and necessary service on the same date of service, the CPT code corresponding to the repeat laboratory test may be reported with modifier 91 appended. For additional information on coding for these codes, please refer to the NCCI Policy Manual for Medicare Services for CY 2019, available at [https://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd/index.html](https://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd/index.html), specifically Chapter I, Section N (Laboratory Panel), and Chapter X, Section C (Organ or Disease Oriented Panels).

Update to Fees

Based on Section 1833(h)(2)(A)(i) of the Act, available at [https://www.ssa.gov/OP_home/ssact/title18/1833.htm](https://www.ssa.gov/OP_home/ssact/title18/1833.htm), the annual update to the local clinical laboratory fees for CY 2019 is 2.30 percent. Beginning January 1, 2019, this update applies only to pap smear tests. For a pap smear test, Section 1833(h)(7) of the Act requires payment to be the lesser of the local fee or the National Limitation Amount, but not less than a national minimum payment amount. However, for pap smear tests, payment may also not exceed the actual charge. The CY 2019 national minimum payment amount is $14.99 (This value reflects the CY 2018 national minimum payment with a 2.3 percent increase or $14.65 times 1.0230). The affected codes for the national minimum payment amount are: 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88164, 88165, 88166, 88167, 88174, 88175, G0123, G0143, G0144, G0145, G0147, G0148, Q0111, Q0115, and P3000.

The annual update to payments made on a reasonable charge basis for all other laboratory services for CY 2019 is 2.3 percent (See 42 CFR 405.509(b)(1)).

The Part B deductible and coinsurance do not apply for services paid under the CLFS.

Access to Data File

Internet access to the CY 2019 CLFS data file will be available after December 1, 2018, at [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html). It will be available in multiple formats, including Excel, text, and comma delimited.
Public Comments and Final Payment Determinations

On June 25, 2018, CMS hosted a public meeting to solicit comments on the reconsidered codes from CY 2018 codes and the new CY 2019 CPT codes. CMS published a notice of the meeting in the Federal Register on March 30, 2018. CMS got recommendations from many attendees, including individuals representing laboratories, manufacturers, and medical societies. CMS posted a summary of the meeting and the tentative payment determinations at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Laboratory_Public_Meetings.html. Additional written comments from the public were accepted until October 22, 2018. CMS also posted a summary of the public comments and the rationale for the final payment determinations at the same webpage shown in the previous sentence.

Pricing Information

The CY 2019 CLFS includes separately payable fees for certain specimen collection methods (codes 36415, P9612, and P9615). The fees have been established in accordance with Section 1833(h)(4)(B) of the Act.

The fees for clinical laboratory travel codes P9603 and P9604 are updated on an annual basis. The clinical laboratory travel codes are billable only for traveling to perform a specimen collection for either a nursing home or homebound patient. If there is a revision to the standard mileage rate for CY 2019, CMS will issue a separate instruction on the clinical laboratory travel fees.

The CY 2019 CLFS also includes codes that have a “QW” modifier to both identify codes and determine payment for tests performed by a laboratory having only a CLIA certificate of waiver.

Mapping Information - Pricing

- Reconsidered code 81326 is priced at the same rate as code 81322.
- Reconsidered code 81334 is priced at the same rate as code 81272.
- New code 0011M is priced at the same rate as code 0005U.
- New code 0012M is priced at the same rate as code 0005U.
- New code 0013M is priced at the same rate as code 0005U.
- New code 0018U is to be gapfilled.
- New code 0019U is to be gapfilled.
- New code 0020U is to be deleted.
- New code 0021U is to be gapfilled.
- New code 0022U is to be gapfilled.
- New code 0023U is to be gapfilled.
- New code 0024U is priced at the same rate as code 83704.
- New code 0025U is priced at the same rate as code G0480.
- New code 0026U is priced at the same rate as code 81545.
- New code 0027U is priced at the same rate as 1.33 times code 0017U.
- New code 0028U is to be deleted.
- New code 0029U is to be gapfilled.
- New code 0030U is to be gapfilled.
• New code 0031U is priced at the same rate as code 81227.
• New code 0032U is priced at the same rate as code 81230.
• New code 0033U is priced at the same rate as 2 times code 81230.
• New code 0034U is priced at the same rate as code 81225 plus code 81335.
• New code 0035U is to be gapfilled.
• New code 0036U is priced at the same rate as code 81415.
• New code 0038U is priced at the same rate as code 82306.
• New code 0039U is priced at the same rate as code 86225.
• New code 0040U is priced at the same rate as 2.5 times code 81206.
• New code 0041U is to be gapfilled.
• New code 0042U is to be gapfilled.
• New code 0043U is to be gapfilled.
• New code 0044U is to be gapfilled.
• New code 0045U is priced at the same rate as code 81519.
• New code 0046U is priced at the same rate as code 81245.
• New code 0047U is priced at the same rate as code 81519.
• New code 0048U is to be gapfilled.
• New code 0049U is priced at the same rate as code 81310.
• New code 0050U is to be gapfilled.
• New code 0051U is priced at the same rate as code 80483.
• New code 0052U is priced at the same rate as code 83701.
• New code 0053U is to be gapfilled.
• New code 0054U is priced at the same rate as code 80482.
• New code 0055U is to be gapfilled.
• New code 0056U is to be gapfilled.
• New code 0057U is to be gapfilled.
• New code 0058U is priced at the same rate as code 86835.
• New code 0059U is priced at the same rate as code 86835.
• New code 0060U is priced at the same rate as code 81420.
• New code 0061U is priced at the same rate as 5 times code 88738.
• New code 81345 is priced at the same rate as code 81403.
• New code 82642 is priced at the same rate as code 82634.
• New code 81333 is priced at the same rate as code 81401.
• New code 81596 is priced at the same rate as code 0001M.
• New code 81518 is priced at the same rate as code 81519.
• New code 81236 is priced at the same rate as code 81406.
• New code 81237 is priced at the same rate as code 81210.
• New code 81233 is priced at the same rate as code 81210.
• New code 81320 is priced at the same rate as code 81225.
• New code 81305 is priced at the same rate as code 81210.
• New code 81443 is priced at the same rate as code 81412.
• New code 81163 is priced at the same rate as code 81406 plus code 81216.
• New code 81164 is priced at the same rate as code 81405 plus code 81406.
• New code 81165 is priced at the same rate as code 81406.
• New code 81166 is priced at the same rate as code 81405.
• New code 81167 is priced at the same rate as code 81406.
• New code 83722 is priced at the same rate as code 83704.
• New code 81306 is priced at the same rate as code 81225.
• New code 81171 is priced at the same rate as code 81401.
• New code 81172 is priced at the same rate as code 81404.
• New code 81204 is priced at the same rate as code 81401.
• New code 81173 is priced at the same rate as code 81405.
• New code 81174 is priced at the same rate as code 81403.
• New code 81177 is priced at the same rate as code 81401.
• New code 81178 is priced at the same rate as code 81401.
• New code 81183 is priced at the same rate as code 81401.
• New code 81179 is priced at the same rate as code 81401.
• New code 81180 is priced at the same rate as code 81401.
• New code 81181 is priced at the same rate as code 81401.
• New code 81182 is priced at the same rate as code 81401.
• New code 81184 is priced at the same rate as code 81401.
• New code 81185 is priced at the same rate as code 81407.
• New code 81186 is priced at the same rate as code 81403.
• New code 81187 is priced at the same rate as code 81401.
• New code 81188 is priced at the same rate as code 81401.
• New code 81189 is priced at the same rate as code 81404.
• New code 81190 is priced at the same rate as code 81403.
• New code 81234 is priced at the same rate as code 81401.
• New code 81239 is priced at the same rate as code 81404.
• New code 81284 is priced at the same rate as code 81401.
• New code 81285 is priced at the same rate as code 81404.
• New code 81286 is priced at the same rate as code 81404.
• New code 81289 is priced at the same rate as code 81403.
• New code 81271 is priced at the same rate as code 81401.
• New code 81274 is priced at the same rate as code 81404.
• New code 81312 is priced at the same rate as code 81401.
• New code 81329 is priced at the same rate as code 81401.
• New code 81336 is priced at the same rate as code 81405.
• New code 81337 is priced at the same rate as code 81403.
• New code 81343 is priced at the same rate as code 81401.
• New code 81344 is priced at the same rate as code 81401.
• New code 87634QW is priced at the same rate as code 87634.
• Existing code 81211 is to be deleted.
• Existing code 81213 is to be deleted.
• Existing code 81214 is to be deleted.
• Existing code 0001M is to be deleted.
Laboratory Costs Subject to Reasonable Charge Payment in CY 2019

Hospital outpatient claims are paid under a reasonable charge basis (see Section 1842(b)(3) of the Act). In accordance with 42 CFR 405.502 through 405.508, the reasonable charge may not exceed the lowest of the actual charge or the customary or prevailing charge for the previous 12-month period ending June 30, updated by the inflation-indexed update. The inflation-indexed update is calculated using the change in the applicable Consumer Price Index (CPI) for the 12-month period ending June 30 of each year, as set forth in 42 CFR 405.509(b)(1). The CPI update for CY 2019 is 2.90 percent.

Manual instructions for determining the reasonable charge payment are available in Chapter 23, Sections 80 through 80.8 of the Medicare Claims Processing Manual at https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c23.pdf. If there is not sufficient charge data for a code, the instructions permit considering charges for other, similar services and price lists.

Services described by HCPCS codes in the following list are performed for independent dialysis facility patents. Chapter 8, Section 60.3 of the Medicare Claims Processing Manual available at https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c08.pdf, instructs that the reasonable charge basis applies. However, when these services are performed for hospital-based renal dialysis facility patients, payment is made on a reasonable cost basis. Also, when these services are performed for hospital outpatients, payment is made under the Hospital Outpatient Prospective Payment System (OPPS).

Codes – Blood Products


Payment for the following codes should be applied to the blood deductible as instructed in Chapter 3, Sections 20.5 through 20.5.4 of the Medicare General Information, Eligibility, and Entitlement Manual:

- P9010, P9016, P9021, P9022, P9038, P9039, P9040, P9051, P9054, P9056, P9057, and P9058.

Note: Biologic product not paid on a cost or prospective payment basis are paid based on Section 1842(o) of the Act. The payment limits based on Section 1842(o), including the payment limits for code P9041, P9045, P9046, and P9047, should be obtained from the Medicare Part B drug pricing files.

Codes – Transfusion Medicine

86850, 86860, 86870, 86880, 86885, 86886, 86890, 86891, 86900, 86901, 86902, 86904, 86905, 86906, 86920, 86921, 86922, 86923, 86927, 86930, 86931, 86932, 86945, 86950, 86960, 86965, 86970, 86971, 86972, 86975, 86976, 86977, 86978, and 86985
Codes – Reproductive Medicine Procedures
89250, 89251, 89253, 89255, 89257, 89258, 89259, 89260, 89261, 89264, 89268, 89272, 89280, 89281, 89290, 89291, 89335, 89337, 89342, 89343, 89344, 89346, 89352, 89353, 89354, and 89356

New Codes Effective October 1, 2018

Proprietary Laboratory Analysis (PLAs)

The following new codes have been added to the national HCPCS file with an effective date of October 1, 2018. These new codes are contractor-priced until they are addressed at the annual Clinical Laboratory Public Meeting, which will take place in June or July of 2019, as they were received after the 2018 public meeting. (MACs will only price PLA codes for laboratories within their jurisdiction.)

- CPT Code: 0062U
  - Short Descriptor: Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score
  - Long Descriptor: Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score
  - Laboratory: SLE-key® Rule Out, Veracis Inc, Veracis Inc

- CPT Code: 0063U
  - Short Descriptor: Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder
  - Long Descriptor: Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder
  - Laboratory: NPDX ASD ADM Panel I, Stemina Biomarker Discovery, Inc, Stemina Biomarker Discovery, Inc d/b/a NeuroPointDX

- CPT Code: 0064U
  - Short Descriptor: Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative
  - Long Descriptor: Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative
  - Laboratory: BioPlex 2200 Syphilis Total & RPR Assay, Bio-Rad Laboratories, Bio-Rad Laboratories

- CPT Code: 0065U
  - Short Descriptor: Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)
  - Long Descriptor: Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)
  - Laboratory: BioPlex 2200 RPR Assay, Bio-Rad Laboratories, Bio-Rad Laboratories

- CPT Code: 0066U
  - Short Descriptor: Placental alpha-micro globulin-1 (PAMG-1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen
  - Long Descriptor: Placental alpha-micro globulin-1 (PAMG-1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen
  - Laboratory: PartoSure™ Test, Parsagen Diagnostics, Inc, Parsagen Diagnostics, Inc, a QIAGEN Company
• **CPT Code: 0067U**
  o Short Descriptor: Onc brst imhchem prfl 4 bmrk
  o Long Descriptor: Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score
  o Laboratory: BBDRisk Dx™, Silbiotech, Inc

• **CPT Code: 0068U**
  o Short Descriptor: Candida species pnl amp prb
  o Long Descriptor: Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. krusei, C. tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species
  o Laboratory: MYCODART Dual Amplification Real Time PCR Panel for 6 Candida species, RealTime Laboratories, Inc

• **CPT Code: 0069U**
  o Short Descriptor: Onc clrct microrna mir-31-3p
  o Long Descriptor: Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score
  o Laboratory: miR-31now™, GoPath Laboratories, GoPath Laboratories

• **CPT Code: 0070U**
  o Short Descriptor: Cyp2d6 gen com&sclt rar vrnt
  o Laboratory: CYP2D6 Common Variants and Copy Number, Mayo Clinic, Laboratory Developed Test

• **CPT Code: 0071U**
  o Short Descriptor: Cyp2d6 full gene sequence
  o Long Descriptor: CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)
  o Laboratory: CYP2D6 Full Gene Sequencing, Mayo Clinic, Laboratory Developed Test

• **CPT Code: 0072U**
  o Short Descriptor: Cyp2d6 gen cyp2d6-2d7 hybrid
  o Long Descriptor: CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)
  o Laboratory: CYP2D6-2D7 Hybrid Gene Targeted Sequence Analysis, Mayo Clinic, Laboratory Developed Test
• CPT Code: 0073U  
  o Short Descriptor: Cyp2d6 gen cyp2d7-2d6 hybrid  
  o Long Descriptor: CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)  
  o Laboratory: CYP2D7-2D6 Hybrid Gene Targeted Sequence Analysis, Mayo Clinic, Laboratory Developed Test  

• CPT Code: 0074U  
  o Short Descriptor: Cyp2d6 nonduplicated gene  
  o Long Descriptor: CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, nonduplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)  
  o Laboratory: CYP2D6 trans-duplication/multiplication non-duplicated gene targeted sequence analysis, Mayo Clinic, Laboratory Developed Test  

• CPT Code: 0075U  
  o Short Descriptor: Cyp2d6 5' gene dup/mlt  
  o Long Descriptor: CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5' gene duplication/multiplication) (List separately in addition to code for primary procedure)  
  o Laboratory: CYP2D6 5' gene duplication/multiplication targeted sequence analysis, Mayo Clinic, Laboratory Developed Test  

• CPT Code: 0076U  
  o Short Descriptor: Cyp2d6 3' gene dup/mlt  
  o Long Descriptor: CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3' gene duplication/multiplication) (List separately in addition to code for primary procedure)  
  o Laboratory: CYP2D6 3' gene duplication/multiplication targeted sequence analysis, Mayo Clinic, Laboratory Developed Test  

• CPT Code: 0077U  
  o Short Descriptor: Ig paraprotein qual bld/ur  
  o Long Descriptor: Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype  
  o Laboratory: M-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry, Mayo Clinic, Laboratory Developed Test  

• CPT Code: 0078U  
  o Short Descriptor: Pain mgt opi use gnotyp pnl  
  o Long Descriptor: Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder
Proprietary Laboratory Analysis (PLAs)

The following new codes have been included in the national HCPCS file correction with an effective date of January 1, 2019 and may need to be manually added to the HCPCS file by the MACs. These new codes are also contractor-priced until they are addressed at the annual Clinical Laboratory Public Meeting, which will take place in June or July 2019 as they were received after the 2018 public meeting. MACs shall only price PLA codes for laboratories within their jurisdiction.

New Codes

- **CPT Code: 0080U**
  - Short Descriptor: ONC LNG 5 CLIN RSK FACTR ALG
  - Long Descriptor: Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy
  - Laboratory: BDX-XL2, Biodesix®, Inc

- **CPT Code: 0081U**
  - Short Descriptor: ONC UVEAL MLNMA MRNA 15 GENE
  - Long Descriptor: Oncology (uveal melanoma), mRNA, gene-expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping genes), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis
  - Laboratory: DecisionDx®-UM, Castle Biosciences, Inc

- **CPT Code: 0082U**
  - Short Descriptor: RX TEST DEF 90+ RX/SBSTS UR
  - Long Descriptor: Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service
  - Laboratory: NextGen Precision™ Testing, Precision Diagnostics LBN Precision Toxicology, LLC

- **CPT Code: 0083U**
  - Short Descriptor: ONC RSPSE CHEMO CNTRST TOMOG
  - Long Descriptor: Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations
  - Laboratory: Onco4D™, Animated Dynamics, Inc
Note: MACs will not search their files to either retract payment or retroactively pay claims; however, they should adjust claims if you bring them to their attention.

ADDITIONAL INFORMATION


If you have questions, your MACs may have more information. Find their website at http://go.cms.gov/MAC-website-list.
### DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 14, 2020</td>
<td>We revised this article to add a link to a related article SE19006. SE19006 states that for CDLTs that are not ADLTs, the data reporting is delayed by one year and must now be reported between January 1, 2021, and March 31, 2021 (previously January 1, 2020, through March 31, 2020). The article also added the “CLFS Data Reporting Delayed” Section on page 24 to summarize the changes.</td>
</tr>
<tr>
<td>January 18, 2019</td>
<td>We revised the article to reflect the revised CR issued on January 17. The revised CR deleted code 0008U from the list of revised codes effective January 1, 2019. We deleted that code from the article. Also, we revised the CR release date, transmittal number, and the web address of the CR.</td>
</tr>
<tr>
<td>December 14, 2018</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2017 American Medical Association. All rights reserved.

Copyright © 2018, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com

The American Hospital Association (the “AHA”) has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.